Trend

Efficacy And Security In A 4-year Follow-up Of The Elevate-tn Examine Comparing Acalabrutinib With Or With Out Obinutuzumab Versus Obinutuzumab Plus Chlorambucil In Treatment-naïve Continual Lymphocytic Leukemia Pmc

Steven Coutre, MD, professor of drugs, Stanford University Medical Center, discusses the eventual position chemotherapy could have in the therapy of chronic lymphocytic leukemia. Acalabrutinib is a next-generation, selective BTK inhibitor accredited for CLL/small lymphocytic…

Read more